Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of MDNA11 in solid tumors

Next Previous
Trial Profile

A phase 2 study of MDNA11 in solid tumors

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MDNA 11 (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms ABILITY

Most Recent Events

  • 04 Aug 2023 New trial record
  • 28 Jul 2023 According to a Medicenna Therapeutics Media Release, the company look forward to evaluating MDNA11 in a Phase 2 patient population in which the patients are less heavily treated in clinically relevant tumor types and may therefore be more likely to respond to immunotherapy treatments such as MDNA11.
  • 28 Jul 2023 According to a Medicenna Therapeutics Media Release,the company will host a conference call on 9 th Aug 2023 to discuss data from cohorts five and six, recommended dose for monotherapy expansion and details on Phase 2 trial design.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top